Novartis chairman rules out merger with Roche: paper

Reuters
Designated successor Reinhardt is seen on a huge TV screen as outgoing utgoing Chairman of Swiss drug maker Novartis Vasella addresses the the annual shareholders general meeting in Basel
.

View photo

Designated successor Joerg Reinhardt is seen on a huge TV screen as outgoing Chairman of Swiss drug maker Novartis Daniel Vasella addresses the the annual shareholders general meeting in Basel February 22, 2013. REUTERS/Arnd Wiegmann

ZURICH (Reuters) - Swiss pharma group Novartis (NOVN.VX) will work more closely with rival Roche (ROG.VX) but rules out a merger, its chairman said in a newspaper interview on Sunday.

Asked whether the two companies wanted to stay independent, Joerg Reinhardt, who took over as Novartis chairman in August, told Swiss newspaper SonntagsZeitung: "Absolutely."

He said, however, that he'd met outgoing Roche Chairman Franz Humer a few weeks ago and was also exchanging emails with his successor Christoph Franz.

"Two pharma groups working in the same location have many topics in common," he said. Both Roche and Novartis are based in Basel in north-western Switzerland.

Asked whether Novartis could sell its stake in Roche that was built up under his predecessor Daniel Vasella, Reinhardt said: "The shares are in good hands with us. For as long as Roche does well, we take pleasure in them."

Novartis holds a third of Roche's bearer shares (RO.SW).

In October, Roche Chief Executive Severin Schwan also knocked back speculation that the company could merge with Novartis.

Reinhardt said in the interview Novartis hoped to conclude an ongoing review of its over-the-counter drugs, animal health and vaccines businesses by the end of the year.

"Then we will know if and how we have to change our structure and organization," he said, adding discussions on possible buys or divestments were under way with partners.

"There are not many players and everybody talks to everybody," he said.

Novartis said in January it was looking at options for the three businesses and wanted the review to be completed by the end of summer.

Reinhardt said Novartis' profitability was only temporarily under pressure due to quality issues in the U.S. and Canada, the fact that the vaccines division was not profitable and falling sales of its former blockbuster Diovan.

"Our profitability will rise again," he said, without giving details.

(Reporting by Silke Koltrowitz; editing by Jason Neely)

Rates

View Comments (3)